A Study to Assess the Anamnestic Immune Response 4 to 8 Years After a Primary Vaccination Series With HBVAXPRO [hepatitis B vaccine recombinant].
Phase of Trial: Phase III
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Merck & Co
- 20 Oct 2009 Actual patient number (1478) added as reported by ClinicalTrials.gov.
- 08 Apr 2009 Actual initiation date changed from 1 Oct 2006 to 1 Sep 2006 as reported by ClinicalTrials.gov.
- 30 Sep 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.